title: Prevention and treatment of hepatitis B recurrence after liver transplantation.
abstract: OBJECTIVE
  To study the efficacy of liver transplantation on end-stage hepatitis B related liver diseases, and the prevention and treatment strategies of hepatitis B recurrence after the transplantation.
  
  
  METHODS
  The efficacy of combined treatment of lamivudine and hepatitis B immune globulin (HBIG) therapy on 24 patients who had received liver transplantation was retrospectively studied.
  
  
  RESULTS
  All the 24 patients with end-stage hepatitis B-related liver diseases treated with lamivudine alone or combined therapy of lamivudine and HBIG showed normal liver function and 21 of them lost hepatitis B virus (HBV) markers. However, the remaining 3 patients became HBsAg positive again soon after liver transplantation.
  
  
  CONCLUSIONS
  Liver transplantation is effective for patients with end-stage hepatitis B-related liver diseases. Combined treatment of lamivudine and HBIG may prevent the recurrence of hepatitis B after the operation.
authors: Department of Surgery, Third Hospital of Peking University, Beijing 100083, China. zhujianpingwz@yahoo.com.cn
authors: Jian-Ping
authors: JP
authors: Zhu
authors: Tong-Lin
authors: TL
authors: Zhang
authors: Lei
authors: L
authors: Li
authors: Jiong
authors: J
authors: Yuan
authors: Shi-Bing
authors: SB
authors: Song
authors: Dian-Rong
authors: DR
authors: Xiu
authors: Kuan-Yong
authors: KY
authors: Hou
authors: Tong
authors: T
authors: Li
authors: Hui
authors: H
authors: Zhuang
mesh_terms: D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D012494:Sampling Studies; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin